Rigel Reports Q4 and FY22 Financial Results and Provides Business Update

(24/7 MARKET NEWS) – Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) reported, after yesterday’s market close, financial results for the fourth quarter and full year ended December 31, 2022, including sales of TAVALISSE tablets.

Highlights include;

• Fourth quarter 2022 Total Revenue of $51.3 million, including TAVALISSE net product sales of $21.9 million and REZLIDHIA net product sales of $0.9 million

• U.S. commercial launch of REZLIDHIA continues to progress and is supported by recent addition to NCCN Guidelines for AML

Rigel Pharmaceuticals is trading at $2.02, up $0.55 (+37.41%), on 1.8 million premarket shares.

Its 52-week trading range is $0.64 to $3.515. It’s just below its key $2.04 resistance level and, if it can break through that on strong volume, it has a few weaker resistance points to its 52 week high, but very doubtful that it gets there on this move.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.